undefined undefined
NaN.000
NaN.00%
Moleculin Biotech (MBRX) has shared an announcement. Moleculin Biotech, Inc. an...
05-16 20:42
An announcement from Moleculin Biotech (MBRX) is now available. Moleculin Biote...
05-15 20:52
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
05-14 22:50
– Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML sub...
05-13 19:30
Moleculin Biotech(MBRX.US):2024年Q1财报实现营收0美元,前值为0美元;每股收益为-2.02美元,前值为-4.13美元,预期值为...
05-11 05:20
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3.53) by 42.78 percent. This is a 51.9 percent increase over losses of $(4.20) per share from
05-11 05:09
Moleculin Biotech (MBRX) has issued an update. Moleculin Biotech, Inc. is set t...
05-08 20:42
Moleculin Biotech (MBRX) has provided an announcement. Moleculin Biotech, Inc. ...
05-02 21:12
Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin a...
05-02 21:00
– Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (M...
05-01 20:50